Curated science news, insights, and data reports from the SciencePreneur team — connecting global science to Indonesia's innovation ecosystem.
Book · Clinical Engineering
A clinical engineering textbook from UI Publishing with Kholis Abdurachim Audah, Ph.D as Chief Editor. Eleven chapters, from hospital technology management to career prospects — written with twelve contributors, most of them Biomedical Engineering students at SGU. Read the opening pages free.
Novel · Science Fiction
A science-fiction novel set in Jakarta: artificial intelligence written directly into human DNA. Read the free preview, Chapters 1–12 — stopping right at the cliffhanger "The Point of No Return" — then get the full novel.
Buy Indonesian raw materials, pair them into 30 products across 12 categories, then decide who owns the product and who owns the IP. How a turn works, why royalty is the heart of the game, and how loans, Global Events and secret missions shape the final score.
Indonesia has about one anatomical pathologist per 100,000 people. What if the slide stayed in the lab and only the image travelled? How the patented scanner (IDS000008696) turns glass into shareable digital images, in four steps and five milestones.
Centella exosomes, salmon DNA (PDRN-inspired), niacinamide and fermented honey in one 20 ml serum, BPOM approved as a cosmetic. What the research on each ingredient says, what the first five users noticed (average scores 8.2–9.6 out of 10), and how to read those results honestly.
Indonesia holds about 10% of the world's flowering plants, yet the national registry lists only 8,483 genetic resources and more than 90% of drug raw materials are imported. How INPL (846 species so far) and CitMed form the front end of a discovery pipeline, and what it will take to make it national.
In the lab, a leaf extract of Sonneratia caseolaris matched vitamin C as an antioxidant (IC50 4.25 vs 5.25 ppm). From that 2022 paper to a shelf at Botani Square: seven steps, a share for mangrove farmers, 1,100 trees planted, and a loop that pays the people who keep the forest standing.
Muhammadiyah has built over 160 universities; Hidayatullah more than 600 pesantren across 100+ districts. An LPDP scheme split Rp20 billion across 26 proposals from 187 submitted. The question is no longer how large the assets are, but how far a piece of work can actually be carried.
A gap is not yet an investment thesis. Five concrete platforms — biodiversity ingredients, GMP and CDMO capacity, research-to-market, advanced therapies, and scientific data — each with what it takes to build and a capital range only where a defensible benchmark exists.
A new financial centre law with its own court and English-language contracts, a political-risk guarantee fund running since 2009, and a health economic zone with Rp5.37 trillion already invested. Enacted law and operating institutions — not aspiration.
Several hundred students in South Jakarta were shown science as a means of making something rather than theory to memorise. Mangrovita — a mangrove fruit juice and a steeped leaf drink — was the working example. Covered by four Indonesian outlets.
Minimum PT PMA paid-up capital fell 75% to Rp2.5 billion in October 2025 — but the Rp10 billion investment threshold, the separate PBF distribution licence and the RPTKA counterpart-training rule all stayed. The eight areas between a market decision and a first commercial sale.
Singapore sells regulatory certainty, Vietnam sells manufacturing cost, Thailand sells clinical maturity. Indonesia has 285.7 million people and the largest pharmaceutical market in ASEAN at US$11 billion — alongside the lowest R&D intensity of the four. Six dimensions compared side by side.
Indonesia produces 29.4% of Southeast Asia's marine natural product research but leads only 20% of it. Of 20,000 registered jamu products, 20 reach clinically-tested status. BPOM puts the gap at Rp350 trillion potential against Rp2 trillion realized.
6,757 patents filed in 2024 — a decade high. Yet under 10% of BRIN's 2,500+ IP assets have ever been commercialized, and private capital funds just 7.3% of national R&D. Mapping the ten stages from laboratory to market, and exactly where each one stalls.
Ten sub-sectors sized and compared side by side — from an US$11 billion pharmaceutical market importing 85% of its active ingredients, to a regenerative-medicine market of just US$14 million that already has its regulations written. Each one with the specific capability gap named.
Healthcare demand, public spending, industrial policy, regulation and foreign capital have started moving at the same time. Inside: the Rp247.3 trillion health budget, four new BPOM regulations, Takeda's US$30 million plasma commitment, and the capability gaps still left open.
280 million people, world-class biodiversity and new ATMP regulation from BPOM — why Indonesia has become one of Southeast Asia's most compelling life-sciences investment frontiers, and where the openings sit.
Five forces shaping biopharma in 2026: AI moving from pilots to the core of R&D, advanced therapies facing a manufacturing reckoning, GLP-1 expanding well beyond obesity, real-world evidence entering pricing talks, and capital discipline reshaping M&A.
Three chapters of one larger book about growing without using up the planet. From Finland's forests and Estonia's bottles to Indonesia's roadmap towards the Golden Indonesia 2045 vision.
How Ki Hajar Dewantara's Taman Siswa philosophy comes alive on a deck of cards — buy raw materials, combine two matched inputs into a product, then decide whether to sell fast or hold. Learning science & research funding without feeling like study.
China has made biomanufacturing and "biotech sovereignty" a pillar of its 15th Five-Year Plan (2026–2030). The four pillars of that ambition, and why they are both an early warning and an opening for a country still importing 90% of its pharmaceutical ingredients.
No major drug was ever born at a lonely desk. From Cambridge's Kendall Square to Singapore's Biopolis — how biotechnology clusters take shape, and what that means for Indonesia and the Sanur Health SEZ in Bali.
An educational map of science-rooted listings on the IDX — pharmaceuticals, laboratories, hospitals, nano and agri-biotech, through to renewable energy. Informational only, not a recommendation or financial advice.
Household waste-sorting rules often meet resistance. Behind them sits solid scientific logic — including why hazardous waste, at just 1% of the total, can contaminate everything else. A constructive case for residents and policymakers alike.
Artificial intelligence is no longer a support tool — it now designs drug molecules, runs clinical trials and operates autonomous laboratories (Lab-in-a-Loop) that learn from their own failures. How AI is rewriting the future of the life sciences.
From Bryan Johnson to BioViva — how biological age is measured, separating fact from hype, and starting with the safest, most measurable step: diagnostics and a doctor's consultation, not extreme experiments.
Microorganisms living on mangroves can produce compounds that fight dangerous pathogens such as MRSA — and they can be harvested without felling a single tree. Explained by Kholis Abdurachim Audah, Ph.D on Meet the Scientist.
Kholis Abdurachim Audah, Ph.D on Indonesia's biosecurity readiness — from the shortage of BSL facilities to a biological defence strategy built on prevention, natural-product research and self-reliant vaccination.
How modern and sustainability-linked financial instruments — from campus prize competitions and thesis licensing to venture debt, green bonds, carbon credits, securitisation and IPOs — could fund Indonesian science from idea to trading floor. Nineteen funding nodes in a single case study.
Indonesia's pharmaceutical industry still imports up to 90% of its active ingredients, even though the country holds some of the richest biodiversity on earth. The government is mapping an import-substitution programme — and that gap is exactly where sciencepreneurship works (INPL, natural-product commercialisation).
How ready is Indonesia's science, research and commercialisation ecosystem against world standards? A visual report maps the country's position across 10 indicators — from PISA scores to patents and deeptech funding. National readiness score: roughly 21/100.
University of Pennsylvania researchers reprogrammed human blood cells into induced pluripotent stem cells (iPS), then grew them inside a living mouse kidney until they became precursors of human sperm cells. A major step in stem-cell research, relevant to therapies built on stem cells and secretome.